KRAS and colorectal carcinoma: Several recent studies indicated that YAP could serve as a novel biomarker for cetuximab resistance in colorectal cancer and head and neck cancer12,45, and our unpublished data showed that knockdown YAP could enhance the sensitivity of K-RAS mutant CRC cells to cetuximab.